Medical Xpress April 15, 2021
by ETH Zurich

Antibodies are not only produced by our immune cells to fight viruses and other pathogens in the body. For a few decades now, medicine has also been using antibodies produced by biotechnology as drugs. This is because antibodies are extremely good at binding specifically to molecular structures according to the lock-and-key principle. Their use ranges from oncology to the treatment of autoimmune diseases and neurodegenerative conditions.

However, developing such antibody drugs is anything but simple. The basic requirement is for an antibody to bind to its target molecule in an optimal way. At the same time, an antibody must fulfill a host of additional criteria. For example, it should not trigger an immune response in the body, it should...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma, Pharma / Biotech, Technology
Digital Innovation Plus AI Tech Can Future-Proof the Enterprise
The AI frenzy could fall flat as companies hoard chips without enough data centers to host them
New AI drug discovery powerhouse Xaira rises with $1B in funding
EU regulation: AI Act will mean a raft of new requirements for ‘high-risk’ systems
Why nurses are protesting AI

Share This Article